Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jiang Liu
Institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
Observed institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
ORCID:
0000-0002-5755-3904
Observed ORCID:
0000-0002-5755-3904
OpenAlex ID:
A5058184357
FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement
2022
·
Timil H. Patel
, Leigh Marcus
, et al.
·
Clinical Cancer Research
·
76
PDF
FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum
2023
·
Sonia Singh
, Diana Bradford
, et al.
·
Clinical Cancer Research
·
70
PDF
FDA Approval Summary: Amivantamab for the Treatment of Patients with Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
2023
·
Katie Chon
, Erin Larkins
, et al.
·
Clinical Cancer Research
·
69
PDF
FDA Approval Summary: Mobocertinib for Metastatic Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
2022
·
Elizabeth S. Duke
, Liza Stapleford
, et al.
·
Clinical Cancer Research
·
60
PDF
FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer
2022
·
Elizabeth S. Duke
, Amy K. Barone
, et al.
·
Clinical Cancer Research
·
60
FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations
2024
·
Gautam U Mehta
, Paz J Vellanki
, et al.
·
The Oncologist
·
50
FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase 1 Mutation
2024
·
Ashley C. Woods
, Kelly J. Norsworthy
, et al.
·
Clinical Cancer Research
·
17
PDF
FDA–AACR Strategies for Optimizing Dosages for Oncology Drug Products: Early-Phase Trials Using Innovative Trial Designs and Biomarkers
2025
·
Olanrewaju O. Okusanya
, Gabriela I. Patilea-Vrana
, et al.
·
Clinical Cancer Research
·
14
PDF
Evaluation and Mitigation of Time‐Dependent Confounding Effects in Conventional Exposure‐Response Analyses for Oncology Drugs
2025
·
Xuefen Yin
, Ye Xiong
, et al.
·
CPT Pharmacometrics & Systems Pharmacology
·
9
FDA–AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Optimized Dosages for Registrational Trials
2025
·
Stacy S. Shord
, Cong Chen
, et al.
·
Clinical Cancer Research
·
7
PDF
FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an IDH1 Mutation
2025
·
Ashley C. Woods
, E. Dianne Pulte
, et al.
·
Clinical Cancer Research
·
7
FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025
·
Robert Q. Le
, Kamar Godder
, et al.
·
Clinical Cancer Research
·
7
FDA–AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Dosages for First-in-Human Trials
2025
·
Hao Zhu
, Alex N. Phipps
, et al.
·
Clinical Cancer Research
·
6
PDF
Data from FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum
2024
·
Sonia Singh
, Diana Bradford
, et al.
·
1
Empowering Clinical Development With Disease Progression Modeling: Recommendations From the Clinical Trials Transformation Initiative
2026
·
Lindsay S. Kehoe
, Shu Chin Ma
, et al.
·
Clinical and Translational Science
Supplementary Table S1: Exploratory analysis of ORR by clinical and demographic subgroups from FDA Approval Summary: Amivantamab for the Treatment of Patients with Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
2025
·
Katie Chon
, Erin Larkins
, et al.
PDF
Data from FDA Approval Summary: Amivantamab for the Treatment of Patients with Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
2025
·
Katie Chon
, Erin Larkins
, et al.
Supplementary Table S1 from FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an IDH1 Mutation
2025
·
Ashley C. Woods
, E. Dianne Pulte
, et al.
PDF
Supplementary Table S3 from FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an IDH1 Mutation
2025
·
Ashley C. Woods
, E. Dianne Pulte
, et al.
PDF
Supplementary Table S2 from FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an IDH1 Mutation
2025
·
Ashley C. Woods
, E. Dianne Pulte
, et al.
PDF
Data from FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an IDH1 Mutation
2025
·
Ashley C. Woods
, E. Dianne Pulte
, et al.
Supplementary Table S6 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025
·
Robert Q. Le
, Kamar Godder
, et al.
PDF
Supplementary Figure S1 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025
·
Robert Q. Le
, Kamar Godder
, et al.
PDF
Supplementary Figure S3 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025
·
Robert Q. Le
, Kamar Godder
, et al.
PDF
Supplementary Table S4 from FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy
2025
·
Robert Q. Le
, Kamar Godder
, et al.
PDF
Show more works
View as search
Works count:
39
Citation count:
453
H-index:
9
I10-index:
8
Year
Topic
Type